Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems
Abstract Cancer remains the second leading cause of death globally, driving the need for innovative therapies. Among natural compounds, maytansinoids have shown significant promise, contributing to nearly 25% of recently approved anticancer drugs. Despite their potential, early clinical trials faced...
Saved in:
| Main Authors: | Matteo Perra, Ines Castangia, Matteo Aroffu, Federica Fulgheri, Rita Abi-Rached, Maria Letizia Manca, Hernán Cortés, María Luisa Del Prado-Audelo, Carla Nomura-Contreras, Alejandra Romero-Montero, Dietrich Büsselberg, Gerardo Leyva-Gómez, Javad Sharifi-Rad, Daniela Calina |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-01-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-01820-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A high content clonogenic survival drug screening identifies maytansine as a potent radiosensitizer for meningiomas
by: Jinxiu Yu, et al.
Published: (2025-03-01) -
A delta-tubulin/epsilon-tubulin/Ted protein complex is required for centriole architecture
by: Rachel Pudlowski, et al.
Published: (2025-03-01) -
Microtubule-modulating drugs alter sensitivity to isoflurane in mice
by: Na Li, et al.
Published: (2025-02-01) -
Microtubule flexibility, microtubule-based nucleation and ROP pattern co-alignment enhance protoxylem microtubule patterning
by: Bas Jacobs, et al.
Published: (2025-01-01) -
Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity
by: Bo He, et al.
Published: (2025-03-01)